Hypertension Diagnostics Announces Second Quarter FY 2005 Results

ST. PAUL, MN February 14, 2005 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second fiscal quarter ended December 31, 2004.

 

     
The Company reported total revenue of $292,015 in the second quarter ended December 31, 2004. Revenue in the prior year’s comparable second quarter totaled $233,721. The Company incurred a net loss of $(439,768) in the quarter ended December 31, 2004, or $(.02) per share, compared with a net loss of $(544,684) in the quarter ended December 31, 2003, or $(.02) per share. Included in the current quarter’s net loss of $(439,768) are total non-cash expense charges of $242,977, evidencing the Company’s progress towards a cash-flow break-even position.

For the six month period ended December 31, 2004, total revenue was $545,436, compared to $482,619 for the same period one year ago. For the six month period ended December 31, 2004, the Company incurred a net loss of $(874,247), or $(.03) per share, compared with a net loss of $(1,001,869), or $(.05) per share, for the same period one year ago. Included in the net loss of $(874,247) for the six months ended December 31, 2004 are total non-cash expense charges of $315,317. The Company reported a cash balance of $1,040,960 on December 31, 2004.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2004 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

View PDF file: Second Quarter FY 2005 Results
 

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: www.HDII.com


Contact: Mark Schwartz, CEO
651-687-9999

Return to the Main HDI Newsroom

   

Back to Top

 

 

     

Copyright © 2007 Hypertension Diagnostics, Inc
Last revised Sunday April 22, 2007
HDI Legal Information